This book investigates and highlights the most critical challenges the pharmaceutical industry faces in an increasingly competitive environment of inflationary R&D investments and tightening cost control pressures. The authors present three sources of pharmaceutical innovation: new management...

The pharmaceutical industry is exposed to severe conditions: while a typical R&D process lasts up to 13 years, only one out of 10,000 substances becomes a marketable product. In addition, markets for pharmaceutical products tend to become more fragmented, leading to an increased risk of market...

The pharmaceutical industry is in a dire situation: R&D still produces no more drugs than 10 years ago, while costs have quadrupled in the meantime. Little advances have been made in innovation efficiency. Worse yet, drug development times are unacceptably long, possible drug development targets...

Deals with the topic of out-licensing as a novel form of risk-sharing collaborations. The phenomenon of out-licensing is illustrated by three major case studies of Novartis, Schering and Roche as well as several smaller case studies. This book applies the Nobel Prize awarded economic theory of...